#SFHS2606169ADecree of 26 March 2026 amending the list of pharmaceutical specialties reimbursed in addition to hospital stays under Article L. 162-22-7 of the Social Security Code
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French decree expands hospital reimbursement (in addition to standard DRG payments) for the immunotherapy drug Keytruda (pembrolizumab). Effective 3 April 2026, four new first-line indications are added for adult patients. These include: (1) combination with enfortumab vedotin for unresectable or metastatic urothelial carcinoma eligible for platinum chemotherapy; (2) combination with chemoradiotherapy (external beam radiotherapy followed by brachytherapy) for FIGO 2014 stage III locally advanced cervical cancer without prior definitive treatment; (3) combination with trastuzumab and platinum + fluoropyrimidine chemotherapy for HER2-positive, PD-L1 CPS ≥1 locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma; and (4) combination with carboplatin and paclitaxel for newly diagnosed advanced or recurrent endometrial cancer eligible for systemic therapy. The product is identified by UCD code 3400894197232 and marketed by MSD France.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Effective date: 3 April 2026
- Adds reimbursement in addition to hospital DRG for Keytruda (pembrolizumab) 25 mg/mL, UCD 3400894197232, marketed by MSD France
- New indication 1: Keytruda + enfortumab vedotin as first-line for unresectable/metastatic urothelial carcinoma eligible for platinum chemotherapy
+ 3 more changes with Pro
Obligations
What this law requires
MSD France must ensure Keytruda (pembrolizumab, UCD code 3400894197232) is billed separately from hospital DRG payments for the four newly approved indications effective 3 April 2026
Healthcare providers must limit Keytruda reimbursement in combination with enfortumab vedotin to first-line treatment only for unresectable or metastatic urothelial carcinoma patients eligible for platinum-based chemotherapy
Healthcare providers must limit Keytruda reimbursement in combination with chemoradiotherapy to adult female patients with FIGO 2014 stage III locally advanced cervical cancer who have not received prior definitive treatment
Healthcare providers must ensure Keytruda combination with trastuzumab and platinum + fluoropyrimidine chemotherapy is used only for first-line treatment of HER2-positive gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥1
Healthcare providers must limit Keytruda combination with carboplatin and paclitaxel to first-line treatment of newly diagnosed advanced or recurrent endometrial cancer in adult female patients eligible for systemic therapy